What do you do when a client lets you know they are going to use psychedelics on their own, as part of a ceremony, spiritual practice or because they’ve heard it can help them? Is there anything you can do to help reduce harm? And what about micro-dosing, which is gaining popularity?
Psychedelic Harm Reduction and Integration (PHRI) is a transdiagnostic and transtheoretical approach that YOU as a mental health professional can take to having conversations with people who have taken psychedelics in clinical or non-clinical settings, or who are seeking help at any stage of psychedelic use. This recording will cover the core concepts of PHRI and its applications, including discussions about microdosing, responding to requests for referrals to non-licensed providers, and working with difficult experiences.
This self-study program consists of 1.0 clock hours of continuing education instruction. Credit requirements and approvals vary by country and local regulatory bodies. Please save the course outline, the certificate of completion you receive from the activity and contact your local regulatory organization to determine specific eligibility and requirements.
| File type | File name | Number of pages | |
|---|---|---|---|
| Attachment |
Manual Notice A seminar manual is not available for this recording. |
Elizabeth Nielson, PhD, is a co-founder of Fluence and a psychologist with a focus on developing psychedelic medicines as empirically supported treatments for PTSD, substance use problems, and mood disorders. Dr. Nielson is a Site Co-Principal Investigator and therapist for an FDA approved Phase 3 clinical trial of MDMA-assisted Psychotherapy for Post-Traumatic Stress Disorder and has served as a therapist on FDA approved clinical trials of psilocybin-assisted treatment of alcohol use disorder, psilocybin-assisted treatment of treatment resistant depression, and earlier phase 2 and 3 trials of MDMA-assisted psychotherapy. Through Fluence, she provides continuing education and training programs for therapists who wish to engage in integration of psychedelic experiences in clinical settings. Her research includes qualitative and mixed-methods projects designed to further understand the phenomenology and mechanisms of change in psychedelic-assisted therapy, including the experiences of trial participants and of the therapists themselves. Having completed an NIH postdoctoral fellowship at NYU, she has published and presented on topics of psychedelic therapist training, therapists’ personal experience with psychedelics, and including psychedelic integration in group and individual psychotherapy.
Speaker Disclosures:
Access never expires for this product.
| 5 |
|
| 4 |
|
| 3 |
|
| 2 |
|
| 1 |
|
Satisfaction Guarantee
Your satisfaction is our goal and our guarantee. Concerns should be addressed to info@pesi.eu.
Please wait ...
